Genenta Science S.p.A. Business Summary

Genenta Science S.p.A. (Nasdaq: GNTA), currently rebranding to Saentra Forge S.p.A. (SAEN), operates as a strategic industrial consolidator following a 2026 pivot from clinical-stage biotechnology to a diversified model targeting biotech, defense, and national security. The company generates revenue through its industrial segment, specifically via the acquisition of ATC, a precision weapons manufacturer projecting €4.0 million in 2026 revenue and over €2.0 million in EBITDA. Its primary business segments are now divided between Strategic Industrial Acquisitions—focused on profitable, national-security regulated Italian firms—and Immuno-oncology, where it maintains its Temferon gene therapy platform through a partnership-driven licensing model rather than internal clinical development. Genenta competes with cell and gene therapy peers such as BioNTech, Fate Therapeutics, and Rocket Pharmaceuticals, positioning itself uniquely as a hybrid entity that leverages industrial cash flows to mitigate the high-risk profile of its oncology pipeline. The company is led by Co-founder, CEO, and Chairman Pierluigi Paracchi, a veteran venture capitalist who holds a 10% stake in the company, and scientific co-founder Dr. Luigi Naldini, the globally recognized pioneer of lentiviral vector technology. The executive suite includes Chief Financial Officer Richard Slansky and Board Member Dr. Francesco Galimi, an oncology R&D expert formerly of Amgen and Novartis who oversees the clinical transition. A pivotal role is played by the Praexidia Foundation, a strategic long-term shareholder consisting of senior Italian government and defense officials, which provides the institutional pedigree necessary for the company’s expansion into defense and aerospace. This leadership team, supported by scientific co-founder Dr. Bernhard Gentner, bridges the gap between advanced genetic medicine and national security-regulated industrial sectors.